Topic summary

Tirzepatide's shorter half-life and its one practical consequence

Compounds › Tirzepatide SURPASS programme randomised trial effect size tirzepatide Wiki

This is a generated summary. It shows the 5 most-liked posts from a topic of 30, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.ekstromTL2Regular13 Nov 2025#3

r.ekstrom, post #1: On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this compound specifically. What should a certificate for this actually carry, given its structure? I suspect the answer differs from… Go to post

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by journalclub_wren on 15 Jul 2026.

11 Feb 2026 — forest_plot: Corrected an arithmetic slip in the second example.
27 Dec 2025 — k.brandl_de: Plain-language pass on the opening paragraph.
19 Mar 2026 — sourced_claims: Restructured into sections so the outline is navigable.
15 Jul 2026 — journalclub_wren: Added the limitations paragraph that review asked for.

Editors: forest_plot, k.brandl_de, sourced_claims, journalclub_wren

Reading rather than contributing, but this is the most useful thread I have found on it.

27 likes in reply to #1 8mo

a.kravchenkoTL218 Nov 2025#6

Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.

18 likes 8mo

d.eriksenTL224 Nov 2025#11

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

29 likes in reply to #1 8mo

a.pereiraTL228 Nov 2025#15

r.mensah, post #2: I had written a reply contradicting the opening post and deleted it. Here is what survived. SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and… Go to post

Worth separating two things that post #11 runs together.

Genuinely open to being wrong about this one.

22 likes in reply to #2 8mo

v.rautioTL28 Dec 2025#25

Building on post #24 rather than restating it.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

27 likes 8mo

Read the full topic (30 posts)

This topic was referenced in

[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggestCompounds › Tirzepatide · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
Tirzepatide molecular mass and the charge states you would expect on ESI Compounds › Tirzepatide effect size SURPASS programme SURMOUNT programme randomised trial Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…	+36	40	44k	11mo
[2026 update] Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…	+58	63	40k	9mo
Reading SURMOUNT-1 without the press release — one year on Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…	+45	50	7.6k	5mo
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…	+62	68	2.6k	29d

Related topics — sharing the tags SURPASS programme, randomised trial, effect size

Topic	Participants	Replies	Views	Activity
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron Solved The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…	+100	104	4.2k	5mo
Retatrutide mass and identity: what a report should show Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. The question about retatrutide mass and identity that I actually…	+22	27	872	22h
Second pass at: Trial registration and comparing the protocol with the paper Evidence › Trials estimand discontinuation & dropout randomised trial open label Posting this under the heading it deserves: Second pass at: Trial registration and comparing the protocol with the paper Everything below is what sits behind that. Two things I would like separated before…	+30	34	33k	13mo
Comparators chosen for regulatory reasons rather than clinical ones Evidence › Trials surrogate endpoints open label estimand randomised trial Pinned Closed On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. An honest uncertainty about comparators chosen for regulatory reasons…		2	27k	14mo
Tirzepatide storage and stability: what is published versus what is assumed Compounds › Tirzepatide SURPASS programme randomised trial SURMOUNT programme effect size On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…	+17	21	17k	12d